ADVICENNE |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.08 EUR | +1.71% |
|
+4.06% | -22.93% |
| 04-08 | Advicenne S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 03-25 | Advicenne: ODD designation in cystinuria | CF |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 27.27M | - | |||||
| 89.49B | ||||||
| 40.67B | ||||||
| 33.15B | ||||||
| 26.45B | ||||||
| 14.69B |
- Stock Market
- Equities
- ALDVI Stock
- Charts Advicenne
- Sector Chart